Basel Medical

BMGL

시가총액 US$625만

Singapore, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL) (the “Company”) today entered into a placement agency agreement with Cathay Securities, Inc., as the placement agent (the “Placement Agent”), as well as a securities purchase agreement with certain purchasers, pursuant to which the Company will issue and sell 6,000,000 units (the “Units”), at a public offering price of US$1.33 per Unit, each consisting of one ordinary share with no par value (each an “Ordinary Share” and collectively the “Ordinary Shares”) or one Pre-Funded Warrant (defined below) of the Company, and one warrant (“Common Warrant”), each to purchase one Ordinary Share. The Ordinary Shares are listed on the Nasdaq Capital Market under the symbol “BMGL”.

Singapore, July 10, 2026 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL) (the “Company”) today announced that it has received notification from Nasdaq that the Company has regained compliance with the Nasdaq minimum bid price rule. On January 22, 2026, Nasdaq notified the Company that its ordinary shares failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Listing Rules of The Nasdaq Stock Market. Since then, Nasdaq has determined that for the last 10 consecutive business days, from June 23, 2026 to July 7, 2026, the closing bid price of the Company's ordinary shares has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2).

BEIJING, June 10, 2026 /PRNewswire/ -- Recently, QingSong Health Corp (2661.HK) and Basel Medical Group Ltd announced the signing of a Memorandum of Strategic Cooperation. The two parties intend to explore cooperation in AI-enabled healthcare services, insurance-related healthcare solutions, and cross-border medical services in Southeast Asia.

SINGAPORE, June 10, 2026 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL) (the “Company”), a medical clinic operator in Singapore, today announced that the Company's board of directors has approved the consolidation of the Company's issued and outstanding shares of the Company on a 1-for-12 ratio with the marketplace effective date of June 22, 2026.

LOS ANGELES, April 23, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Basel Medical Group Ltd (“Basel” or “the Company”) (NASDAQ: BMGL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Basel Medical Group Ltd. (NASDAQ: BMGL) resulting from allegations that Basel Medical may have issued materially misleading business information to the investing public. So what: If you purchased Basel Medical securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency.

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Basel Medical Group Ltd. (NASDAQ: BMGL) resulting from allegations that Basel Medical may have issued materially misleading business information to the investing public. So what: If you purchased Basel Medical securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency.

Singapore, March 24, 2026 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL) (the “Company”) today announced that it has received notification from Nasdaq that based on the Company's amended annual report on Form 20-F for the fiscal year of 2025, which was filed with the SEC on March 13, 2026, Nasdaq Staff has now determined that the Company has complied with the periodic filing requirement for The Nasdaq Stock Market under Listing Rule 5250(c)(1) (the “Periodic Filing Rule”). Accordingly, the prior deficiency relating to the Periodic Filing Rule has now been resolved.

Singapore, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL) (the “Company”), today announced that it has received notification from Nasdaq that based on the closing bid price of the Company's shares for the last 30 consecutive business days, the Company no longer meets the requirements under Nasdaq's Listing Rules (the “Rules”) for listed securities to maintain a minimum bid price of $1 per share.

Singapore, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL) (the “Company”), today announced that it has received notification from Nasdaq that the Company's annual report on Form 20-F for the fiscal year ended June 30, 2025 was incomplete and that the Company is delinquent in its filing obligations. This was because such report failed to include an opinion from the Company's auditor, NLA DFK Assurance PAC, on the Company's financial statements.